Business Description
Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.
Business History
Price Overview
Last updated: May 11, 2026 12:49pm (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -2.01
Total Equity: $461.88M
Shares: 114,070,225
Total Debt: $138.63M
Cash: $31.89M
EBITDA: -$2.49M
Total Debt: $138.63M
Cash: $31.89M
Revenue: $272.07M
Revenue: $272.07M
Revenue: $272.07M
Total Equity: $461.88M
Tax Rate: 5.4%
Equity: $461.88M
Total Debt: $138.63M
Cash: $31.89M
Current Liabilities: $74.55M
Long-Term Debt: $135.75M
Total Debt: $138.63M
Total Equity: $461.88M
Shares: 114,070,225
Shares: 114,070,225
CapEx: -$3.43M
Shares: 114,070,225
Stock Price: $1.80
Net Income: -$229.75M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $142.5M | $166.1M | $218.1M | $273.9M | $272.1M |
| Cost of Revenue | $55.0M | $126.7M | $76.6M | $82.1M | $148.2M |
| Gross Profit | $87.4M | $39.4M | $141.6M | $131.7M | $123.8M |
| Operating Expenses | $89.1M | $113.7M | $223.5M | $185.3M | $185.5M |
| Operating Income | -$1.6M | -$74.3M | -$81.9M | -$58.6M | -$61.7M |
| Net Income | -$19.6M | -$116.6M | -$90.0M | -$42.4M | -$229.7M |
| EBITDA | $15.0M | -$99.3M | -$33.5M | $28.6M | -$2.5M |
| EPS | $-0.45 | $-1.08 | $-0.89 | $-0.39 | $-2.01 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $12.8M | $8.7M | $22.6M | $14.8M | $31.9M |
| Total Current Assets | $59.0M | $91.0M | $107.3M | $103.6M | $126.9M |
| Total Assets | $184.6M | $1.1B | $1.0B | $975.9M | $816.2M |
| Current Liabilities | $40.8M | $72.5M | $62.7M | $76.9M | $74.5M |
| Long-Term Debt | $103.4M | $159.2M | $151.3M | $137.1M | $135.8M |
| Total Liabilities | $145.3M | $290.2M | $273.4M | $245.9M | $316.1M |
| Total Equity | $39.2M | $639.2M | $624.6M | $662.3M | $461.9M |
| Retained Earnings | -$64.8M | -$156.8M | -$246.8M | -$289.2M | -$519.0M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $3.5M | -$85.0M | -$29.8M | -$8.8M | -$12.8M |
| Capital Expenditure | -$1.3M | -$2.5M | -$2.0M | -$3.0M | -$3.4M |
| Free Cash Flow | $2.2M | -$87.5M | -$31.8M | -$11.8M | -$16.2M |
| Acquisitions (net) | $0 | -$587.7M | $0 | $0 | -$2.6M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $4.9M | -$3.3M | $12.4M | -$6.3M | $15.6M |
Analyst Estimates (Annual)
| Metric | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Revenue |
$272.4M $270.6M – $275.1M
|
$275.4M $274.0M – $276.7M
|
$291.9M $283.5M – $300.3M
|
$306.4M $292.3M – $320.6M
|
| EBITDA |
-$30.0M -$30.3M – -$29.8M
|
-$30.3M -$30.4M – -$30.1M
|
-$32.1M -$33.0M – -$31.2M
|
-$33.7M -$35.3M – -$32.2M
|
| Net Income |
-$19.4M -$30.5M – -$8.3M
|
-$200.4M -$211.3M – -$189.6M
|
-$69.2M -$73.0M – -$65.4M
|
-$65.8M -$69.4M – -$62.2M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +16.6% | +31.3% | +25.5% | -0.7% |
| Gross Profit Growth | -54.9% | +259.0% | -7.0% | -6.0% |
| Operating Income Growth | -4,470.4% | -10.3% | +28.5% | -5.3% |
| Net Income Growth | -495.7% | +22.8% | +52.8% | -441.3% |
| EBITDA Growth | -759.6% | +66.2% | +185.4% | -108.7% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-03-18 | Brousset Michel | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Brousset Michel | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Brousset Michel | 4,135,340.00 | $3.98 | $16.5M | |
| 2026-03-18 | Brousset Michel | 264,294.00 | $0.00 | $0 | |
| 2026-03-18 | Brousset Michel | 2,311,113.00 | $11.50 | $26.6M | |
| 2026-03-18 | Brousset Michel | 1,424,166.00 | $0.00 | $0 | |
| 2026-03-18 | Souza Cristiano | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Souza Cristiano | 712,083.00 | $0.00 | $0 | |
| 2026-03-18 | Souza Cristiano | 4,892,767.00 | $11.50 | $56.3M | |
| 2026-03-18 | Thompson Motta Roberto Moses | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Thompson Motta Roberto Moses | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Chatterley Aaron | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Chatterley Aaron | 18,727.00 | $0.00 | $0 | |
| 2026-03-18 | Dutra Felipe | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Manfredi Manuel | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Manfredi Manuel | 79,289.00 | $0.00 | $0 | |
| 2026-03-18 | Hickman Juliette | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Hickman Juliette | 18,727.00 | $0.00 | $0 | |
| 2026-03-18 | Sebti Hind | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Sebti Hind | 1,594,660.00 | $3.98 | $6.3M |